NEXGEL New Strategic Partner, Sequence LifeScience(TM), Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Stock Information for NexGel Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NexGel Inc

NEXGEL Appoints Ian Blackman as Chief Financial Officer
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.